Table 1.

Summary of current clinical trial PFS data on which statistical calculations are based

	KRAS unknown	KRAS WT	KRAS mutant	KRAS G13D
BOND study [1] cetuximab alone vs cetuximab + irinotecan	6 m PFS = 8 % vs. 30 %	NA	NA	NA
CO.17 [4] cetuximab vs best supportive care	N/A	6 m PFS cetuximab = 30 %	6 m PFS < 5 %
De Roock [11] cetuximab vs no cetuximab	N/A	Median PFS 4.2 m vs 1.9 m	Median PFS 1.9 m vs 1.8 m	Median PFS 4.0 m vs 1.7 m
Tepjar [12] cetuximab vs no cetuximab as 1st line treatment	Not relevant	Median PFS 9.6 m vs 7.6 m	Median PFS 6.7 m vs 8.1 m	Median PFS 7.4 m vs 6.0 m